Berberine metabolizing enzymes

Berberine metabolizing enzymes encompass a diverse group of Phase I and Phase II enzymes responsible for the biotransformation and clearance of the isoquinoline alkaloid berberine. In the liver, Phase I metabolism is primarily mediated by Cytochrome P450 (CYP) enzymes, including CYP2D6, CYP1A2, CYP3A4, CYP2C19, and CYP2C9, which facilitate the oxidative demethylation of berberine into metabolites like thalifendine and berberrubine (PMID: 21413894). Phase II metabolism involves the conjugation of these metabolites by UDP-glucuronosyltransferases (UGTs), such as UGT1A1 and UGT1A9, and sulfotransferases (SULTs) to enhance water solubility for excretion (PMID: 21812954). Furthermore, gut microbiota-derived nitroreductases are essential for converting berberine into dihydroberberine, a form that is more readily absorbed in the intestines (PMID: 25533011). Beyond being substrates, berberine and its metabolites can inhibit several of these enzymes, particularly CYP2D6 and CYP3A4, leading to potential drug-drug interactions with narrow therapeutic index medications like cyclosporine (PMID: 22537016). Understanding the activity and genetic variability of these enzymes is crucial for predicting berberine's efficacy and safety profile in clinical applications.

Other names

Berberine-metabolizing enzymesCYP enzymes involved in berberine metabolismBerberine biotransformation enzymes

Berberine acts as a substrate for oxidative demethylation by CYP enzymes and as a competitive or non-competitive inhibitor of CYP2D6, CYP3A4, and CYP2C9.